Jemperli is currently approved for use in combination with standard-of-care chemotherapy combination, carboplatin and paclitaxel for treating adult patients with primary advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability-high in Europe. Shares of GSK have rallied 9.2% so far this year against the industry's decline of 5.8%. Jemperli is a key drug that aids GSK's oncology sales. The drug generated sales worth £80 million in the first quarter of 202 ...